Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?

V Czernecki, B Pillon, J L Houeto, M L Welter, V Mesnage, Y Agid, B Dubois, V Czernecki, B Pillon, J L Houeto, M L Welter, V Mesnage, Y Agid, B Dubois

Abstract

Objective: High frequency stimulation of the subthalamic nucleus (STN) dramatically decreases motor disability in patients with Parkinson"s disease (PD), but has been reported to aggravate apathy. The aim of this study was to analyse the effect of STN stimulation on motivation and reward sensitivity in a consecutive series of PD patients.

Methods: Apathy and reward sensitivity (Apathy Scale, Stimulus-Reward Learning, Reversal, Extinction, and Gambling tasks) were assessed in 18 PD patients treated by bilateral STN stimulation ("on" and "off" conditions) compared with 23 matched patients undergoing long term treatment with levodopa ("on" and "off" conditions).

Results: Apathy decreased under both STN stimulation and levodopa treatment, whereas explicit and implicit stimulus reward learning was unchanged.

Conclusions: Bilateral STN stimulation in PD patients does not necessarily have a negative effect on motivation and reward sensitivity and can even improve apathy provided patients have been appropriately selected for neurosurgery.

References

    1. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):701-7
    1. Lancet. 2002 Oct 26;360(9342):1302-4
    1. Science. 1997 Mar 14;275(5306):1593-9
    1. Brain. 2000 Jun;123 ( Pt 6):1142-54
    1. Brain Cogn. 2000 Apr;42(3):324-47
    1. Neurology. 2000 Aug 8;55(3):411-8
    1. Prog Brain Res. 1990;85:119-46
    1. Brain. 2000 Oct;123 ( Pt 10):2091-108
    1. Mov Disord. 2003 May;18(5):524-30
    1. J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42
    1. N Engl J Med. 1998 Oct 15;339(16):1105-11
    1. Brain. 2002 Mar;125(Pt 3):575-83
    1. Mov Disord. 2001 Sep;16(5):867-75
    1. Mov Disord. 1999 Jul;14(4):572-84
    1. J Neurosurg. 2000 Apr;92(4):615-25
    1. Brain. 2002 Sep;125(Pt 9):1995-2004
    1. N Engl J Med. 1999 May 13;340(19):1476-80
    1. J Neurosci. 1998 Jan 1;18(1):428-37
    1. Neuropsychologia. 2000;38(5):596-612
    1. Semin Clin Neuropsychiatry. 1996 Oct;1(4):304-314
    1. Mov Disord. 2002;17 Suppl 3:S116-22
    1. Cereb Cortex. 2000 Mar;10(3):295-307
    1. Psychiatry Res. 2002 Jun 15;114(2):103-11
    1. Br J Psychiatry. 1979 Apr;134:382-9
    1. Nature. 1996 Mar 7;380(6569):69-72
    1. Clin Neuropharmacol. 2001 Nov-Dec;24(6):346-51
    1. Ann Neurol. 1999 Aug;46(2):217-23
    1. J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1518-24
    1. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):174-9
    1. Cortex. 1976 Dec;12(4):313-24
    1. Neurology. 1999 Apr 12;52(6):1227-9
    1. J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9
    1. Neuropsychologia. 2002;40(13):2257-67
    1. J Neurosci. 2002 Jan 15;22(2):592-9

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren